Shionogi
4507.T4507.T · Stock Price
Historical price data
Overview
Shionogi is a premier, discovery-based Japanese pharmaceutical company with a 65+ year legacy in antibiotic innovation and a mission to supply the best possible medicine to protect patient health. The company has successfully diversified its pipeline beyond its core infectious disease expertise into antivirals, CNS disorders, and rare diseases, while maintaining a steadfast commitment to combating antimicrobial resistance (AMR). Its strategy combines deep in-house R&D capabilities with strategic global partnerships and licensing to accelerate development and commercialize novel therapeutics for serious unmet medical needs worldwide.
Technology Platform
Deep expertise in small-molecule drug discovery and development, with specialized platforms in anti-infective medicinal chemistry, virology, and strategic use of AI/digital health partnerships.
Pipeline
143| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Naldemedine + Placebo | Opioid-Induced Constipation (OIC) | Approved | |
| Rosuvastatin + HMG CoA inhibitor | Hypercholesteremia | Approved | |
| Statin | Ischemic Stroke | Approved | |
| Cefiderocol | Cystic Fibrosis | Approved | |
| Duloxetine + Pregabalin + Placebo | Diabetic Peripheral Neuropathic Pain | Approved |
FDA Approved Drugs
3Opportunities
Risk Factors
Competitive Landscape
Shionogi competes as a focused innovator against large pharma in infectious diseases (e.g., Pfizer, Merck in COVID-19; Gilead in HIV) and a shrinking cohort in antibiotics. Its competitive edge lies in deep, sustained expertise in complex anti-infective R&D and a strategic partnership model that expands its reach without overextending resources.
Competitors
Company Timeline
Founded in Osaka, Japan
FDA Approval: METHYLIN
FDA Approval: MULPLETA
FDA Approval: FETROJA